PARK2 loss promotes cancer progression via redox-mediated inactivation of PTEN. Academic Article uri icon

Overview

abstract

  • Cancer and Parkinson disease (PD) derive from distinct alterations in cellular processes, yet there are pathogenic mutations that are unequivocally linked to both diseases. Here we expand on our recent findings that loss of parkin RBR E3 ubiquitin protein ligase (PRKN, best known as PARK2)-which is genetically linked to PD-promotes cancer progression via redox-mediated inactivation of phosphatase and tensin homolog (PTEN) by S-nitrosylation.

publication date

  • May 19, 2017

Identity

PubMed Central ID

  • PMC5706935

Scopus Document Identifier

  • 85050761434

Digital Object Identifier (DOI)

  • 10.1080/23723556.2017.1329692

PubMed ID

  • 29209642

Additional Document Info

volume

  • 4

issue

  • 6